SLU-PP-332 vs Tesofensine
A side-by-side research comparison of SLU-PP-332 and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | SLU-PP-332 | Tesofensine |
|---|---|---|
| Full name | SLU-PP-332 (ERR Agonist) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | Phase 3 Clinical Trial |
| Mechanism | A pan-ERR (estrogen-related receptor alpha/beta/gamma) agonist. ERRs are master regulators of mitochondrial biogenesis and oxidative metabolism, so activation upregulates fat oxidation and the genetic program normally triggered by endurance exercise. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | ~426 Da (small molecule, not a peptide) | 329.4 Da |
| Half-life | Not well characterized in humans | 8-10 days |
| Bioavailability | Studied via injection in animals; oral activity under investigation | High (oral ~93%) |
| Typical dose | No established human dose | 0.25-0.5 mg |
| Frequency | Unknown | Once daily |
| Route | Injection (preclinical) | Oral |
SLU-PP-332 reported benefits
- Increases mitochondrial fat-burning (preclinical)
- Improved endurance in animals
- Reduced fat gain without appetite change (animals)
- Acts as an "exercise mimetic"
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.